ImmunOs Therapeutics AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImmunOs Therapeutics AG
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
It has proved tricky of late for European biotechs to raise funds, but Switzerland's ImmunOs has gathered a group of top-tier US and European investors to help push lead asset IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, towards the clinic.